Additionally, the antitumor activity of SSOs was also demonstrated in vivo in a mouse model of melanoma lung metastases where the systemic administration of Bcl-x SSO using a lipid nanoparticle redirected Bcl-x splicing and led to a significant reduction in tumor burden in treated mice [183]. The gene discussed is BCL2L1; the disease is neoplasm.